IMA (ImageneBio) Ending Cash Position: $76.05 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMA ImageneBio Inc IMA
10 GF Score
Price $5.59
! 3 Warning Signs
View Full Analysis

What is ImageneBio Ending Cash Position?

ImageneBio IMA +0.36% 10 Ending Cash Position is $76.05 Mil as of Mar. 2026. GuruFocus rates IMA with a GF Score™ of 10/100. The stock has 3 warning signs investors should review.

ImageneBio's Ending Cash Position for the quarter that ended in Mar. 2026 was $76.05 Mil.

ImageneBio's quarterly Ending Cash Position increased from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($94.53 Mil) but then declined from Dec. 2025 ($94.53 Mil) to Mar. 2026 ($76.05 Mil).

ImageneBio's annual Ending Cash Position declined from Dec. 2023 ($15.32 Mil) to Dec. 2024 ($12.12 Mil) but then increased from Dec. 2024 ($12.12 Mil) to Dec. 2025 ($94.53 Mil).

ImageneBio Ending Cash Position Related Terms

ImageneBio Ending Cash Position Historical Data

* Premium members only.

The historical data trend for ImageneBio's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImageneBio Ending Cash Position Chart

ImageneBio Annual Data
Trend Dec23 Dec24 Dec25
Ending Cash Position
15.32 12.12 94.53

ImageneBio Quarterly Data
Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial 12.12 4.92 0.00 94.53 76.05
IMA
10GF Score
ImageneBio Inc IMA
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ImageneBio Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

ImageneBio's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=12.118+82.414
=94.53

ImageneBio's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=94.532+-18.484
=76.05

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $76.05 Mil mean?
ImageneBio (IMA) has a Ending Cash Position of $76.05 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on ImageneBio and its competitors.
Is ImageneBio's Ending Cash Position too high?
ImageneBio's current Ending Cash Position is $76.05 Mil. Overall, ImageneBio has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does ImageneBio's Ending Cash Position compare to HYFT and CING?
ImageneBio's Ending Cash Position of $76.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on ImageneBio and its competitors. ImageneBio's current Ending Cash Position is $76.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImageneBio stock overvalued right now?
ImageneBio (IMA) has a current Ending Cash Position of $76.05 Mil. The current Ending Cash Position is $76.05 Mil. ImageneBio's overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For ImageneBio (IMA), the current Ending Cash Position is $76.05 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ImageneBio Business Description

Address 12526 High Bluff Drive, Suite 345, San Diego, CA, USA, 92130
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
10GF Score

Get the complete analysis for IMA

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.59
Price